Table 3.
Detection of surface markers on CD14+ monocytes after LTA and trimodulin treatment.
| LTAa (µg/ml) | Trimodulinb (mg/ml) | TLR2 (n = 6)c | TLR4 (n = 4)c | CD16 (n = 6)c | CD64 (n = 6)c | CD11b (n = 5)c | CD11c (n = 4)c | HLA-DR (n = 5)c |
|---|---|---|---|---|---|---|---|---|
| 0 | 4.9 ± 2.4 | 3.2 ± 2.0 | 50.0 ± 21.8 | 19.6 ± 4.7 | 142.5 ± 31.6 | 126.5 ± 18.6 | 193.6 ± 85.5 | |
| 0 | 0.5 | 3.3 ± 0.8 | 1.8 ± 0.5 | 57.8 ± 34.4 | 29.7 ± 12.2 | 136.1 ± 24.9 | 138.9 ± 8.3 | 142.4 ± 73.3 |
| 5 | 2.6 ± 1.2 | 1.9 ± 0.5 | 40.2 ± 15.6 | 46.1 ± 23.8* | 94.9 ± 20.6* | 123.5 ± 5.3 | 107.1 ± 44.0 | |
|
| ||||||||
| 0 | 4.7 ± 2.0 | 2.5 ± 0.5 | 67.4 ± 30.5 | 19.7 ± 7.4 | 127.9 ± 27.3 | 130.5 ± 17.4 | 143.8 ± 80.5 | |
| 1 | 0.5 | 3.1 ± 1.3 | 2.2 ± 0.9 | 53.8 ± 22.2 | 15.6 ± 6.1 | 115.6 ± 1 9.3 | 131.5 ± 3.8 | 130.4 ± 64.6 |
| 5 | 2.2 ± 1.0* | 1.4 ± 0.6* | 45.6 ± 5.5 | 32.2 ± 16.5 | 85.7 ± 10.0* | 104.4 ± 12.0* | 117.9 ± 44.2 | |
|
| ||||||||
| 0 | 7.1 ± 3.4 | 2.6 ± 1.6 | 128.9 ± 54.1 | 93.8 ± 41.8 | 55.3 ± 31.7 | 59.4 ± 5.3 | 24.6 ± 16.7 | |
| 10 | 0.5 | 4.6 ± 1.6 | 1.1 ± 0.5 | 81.6 ± 27.2 | 66.7 ± 29.7 | 67.4 ± 21.9 | 63.2 ± 8.9 | 26.7 ± 13.6 |
| 5 | 3.5 ± 1.3* | 0.9 ± 0.3 | 36.0 ± 5.2** | 54.2 ± 32.6 | 35.8 ± 12.9 | 49.4 ± 6.5 | 30.3 ± 17.6 | |
a
Total endotoxin treatment time (72 h) on healthy donor PBMCs.
b
Treatment 24 h after initiation of LTA stimulation.
c
Mean +/− SD values were obtained from four to six donors (values represent mean cell fluorescence).
*P ≤ 0.05 and **P ≤ 0.01 statistically different compared to trimodulin untreated control (two-tailed t-test).
Bold numbers: increase or decrease is different with P ≤ 0.05 for LTA stimulation alone compared to unstimulated cells (two-tailed t-test).LTA: lipoteichoic acid.